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Background: In Malaysia, more than 330 000 individuals are esti- from 2026 to 2030. Conclusions: This exercise was one of the first
mated to be chronically infected with hepatitis C virus (HCV), but
less than 2% have been treated to date. Objectives: To estimate the
required coverage and costs of a national screening strategy to
inform the launch of an HCV elimination program. Methods: We
designed an HCV screening strategy based on a “stepwise” approach.
This approach relied on targeting of people who inject drugs in the
early years, with delayed onset of widespread general population
screening. Annual coverage requirements and associated costs were
estimated to ensure that the World Health Organization elimination
treatment targets were met. Results: In total, 6 million individuals
would have to be screened between 2018 and 2030. Targeting of
people who inject drugs in the early years would limit annual
screening coverage to less than 1 million individuals from 2018 to
2026. General population screening would have to be launched by
2026. Total costs were estimated at MYR 222 million ($58 million).
Proportional to coverage targets, 60% of program costs would fallConflicts of interest: The authors have indicated that they have n
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https://doi.org/10.1016/j.vhri.2018.12.005attempts to conduct a detailed analysis of the required screening
coverage and costs of a national HCV elimination strategy. These
findings suggest that the stepwise approach could delay the onset of
general population screening by more than 5 years after the pro-
gram's launch. This delay would allow additional time to mobilize
investments required for a successful general population screening
program and also minimize program costs. This strategy prototype
could inform the design of effective screening strategies in other
countries.
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Emerging Challenges in the Elimination of Hepatitis C Virus:
Finding the “Missing Millions”
Despite increasing access to and affordability of highly effective
treatments for hepatitis C virus (HCV) infection, that is, direct-
acting antivirals (DAAs), only 1% of infected individuals have
been treated globally.1 One of the emerging major challenges toscaling up HCV treatment is the fact that only 10% of HCV
chronically infected individuals have been diagnosed. The World
Health Organization (WHO) HCV elimination targets call for 90%
of infected patients to be diagnosed and 80% of eligible patients
to be treated by 2030.1 As countries strive for elimination, more
than 60 million currently undiagnosed individuals will have to be
identified and initiated on treatment. The effectiveness of gov-
ernments and their partners to design and execute effective
screening strategies to identify these “missing millions” will be ao conflicts of interest with regard to the content of this article.
ealth Advisors, 780 Boylston St, Apt 16J, Boston, MA 02199.
9 October 2018, accepted 3 December 2018.
r health economics and outcomes research. Published by Elsevier
ttp://creativecommons.org/licenses/by-nc-nd/4.0/).
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realized.
Despite screening being important, national HCV planning
efforts can still initiate an elimination program before having a
fully developed national screening strategy. In most countries,
there is a pool of already diagnosed patients with HCV awaiting
treatment at the launch of a national program. When countries
first launch treatment campaigns, this pool of patients is usually
the first to gain access, for both ethical and practical reasons.
Moreover, recent examples of hepatitis treatment scale-up stra-
tegies suggest that some countries might prefer modest scale-up
in the early years to allow for capacity building and resource
mobilization.2 As scale-up efforts move beyond the initial phase
and annual treatment targets necessarily increase to keep pace
with elimination ambitions, large-scale treatment programs will
have to develop effective strategies to identify undiagnosed
chronically infected individuals.HCV Context in Malaysia
In Malaysia, the HCV epidemic is a public health priority and
places enormous strain on the health system. In 2009, there were
an estimated 335000 people aged 15 to 64 years livingwith chronic
HCV infection, reflecting an estimated HCV antibodyepositive
prevalence of 2.5% among the adult population.3 Among people
who inject drugs (PWID), anti-HCV prevalence is estimated to be
alarmingly high at 67%.3
Less than 2% of the estimated total infected population was
treated for HCV from 2003 to 2017, about 600 patients annually in
recent years.4 Before 2018, patients could access DAAs only
through purchasing them in the private sector or through drug
trial participation. The Malaysian Ministry of Health (MMOH)
announced that it would launch a national HCV treatment pro-
gram in 2018,5,6 following in the footsteps of other low- and
middle-income countries (LMICs) that have launched large-scale
DAA treatment programs, notably, Egypt, Mongolia, and Georgia.
Government negotiations on DAA prices have been ongoing in
Malaysia, and there have been efforts to project the HCV-related
disease burden under various treatment scenarios and to esti-
mate the treatment coverage and associated treatment costs
required tomeet theWHO treatment targets.7 Thismodeling work
suggests that to meet the WHO targets, 270 000 patients will have
to be treated between 2018 and 2030. The total cost of patient care,
management, and drug treatment was estimated at $890 million7
under one possible scale-up strategy that meets the WHO 2030
treatment targets. This scale-up begins with 5000 treated patients
in 2018, increases to 20000 annually in 2023, peaks at 30 000 from
2025 to 2028, and then falls to 25 000 per year in 2029 and 2030.Screening Efforts in Malaysia
Fully committing to elimination will require Malaysia to find its
ownmissingmillions. As of 2017, about 12 500 infected individuals
were known to be awaiting access to DAAs and were being
monitored by specialists.8 The MMOH currently sponsors volun-
tary screening at family medicine clinics (community primary
healthcare clinics) and mandatory screening at dialysis centers
and blood banks. These efforts, on the basis of national hepatitis C
notification data, yielded about 2000 chronic HCV cases annually
before 2016 and 3000 chronic HCV cases in both 2016 and 2017 (R.
Mohamed, MD, email communication, April 2018).9 For PWID,
annual HCV screening is a policy in opioid substitution therapy
settings, but is unreliably and inconsistently enforced.
HCV screening is becoming an increasing public health prior-
ity; in 2018, several nongovernmental organizations (NGOs)
launched a campaign, initially in the Klang Valley region, in
collaboration with private methadone maintenance therapy(MMT) centers, private needle and syringe exchange programs
(NSPs), and family medicine specialists who volunteer to
participate.
Interviewswith leading clinicians, MMOH representatives, and
other stakeholders have indicated that a large-scale screening
program will require further decentralization of HCV screening
and treatment to family medicine clinics in all states of Malaysia.
Building this capacity nationwide will require major investments
in human resources and training that will take years.
Objectives
Our objectives were two-fold. We aimed to estimate both (1) the
required annual screening coverage targets and (2) the cost of a
national screening strategy that allow a sufficient number of pa-
tients to be identified tomeet theWHO treatment targets and over
time implement increasingly decentralized screening to family
medicine clinics. Besides helping to inform planning efforts in
Malaysia, as one of the first detailed costing exercises of a national
screening program in an LMIC, our findings could serve as a pro-
totype for other countries wishing to design screening strategies
to meet the WHO HCV treatment targets.Methods
Screening Strategy Design: Stepwise Targeting
Our strategy implements decentralized general population
screening to keep Malaysia on track to meet its HCV treatment
goals while the capacity and resources for widespread screening
at family medicine clinics are mobilized. Baseline screening ac-
tivities serve as the foundation for this screening strategy. The
initial phase prioritizes targeting of PWID to delay the onset of
decentralized, general population screening and achieve pro-
grammatic efficiency, because efforts to screen this high-
prevalence population within MMT programs are already under-
way. PWID belong to the largest high-risk group for HCV in
Malaysia and were subsequently divided into the following sub-
groups: current MMT clients, current and former NSP clients,
relapsed MMT clients, other active PWID, and former PWID. In the
final phase, intensive general population screening at family
medicine clinics kicks off after there are no longer enough in-
fections among PWID to yield enough treatment-eligible in-
dividuals to meet targets. In our proposed strategy, general
population screening represents the scale-up of active screening
efforts in family medicine clinics where family medicine spe-
cialists would use a short questionnaire to “pre-screen” for high-
risk behaviors. We called this strategy the “stepwise” approach
(see Fig. 1).
Calculating Screening Coverage
Screening coverage was reverse-calculated along the cascade of
care from a required yield to sufficiently meet annual treatment
targets. Figure 2 illustrates the calculation process. For baseline
screening activities that were assumed to produce a constant
screening yield, the number of filled treatment spots was deter-
mined after accounting for effective linkage to care, or the per-
centage of the screening yield successfully initiated on
treatment. Then, the required screening yield from PWID tar-
geting and general population screening to fill the remaining
treatment spots was calculated, after again accounting for link-
age to care. For the treatment targets to be met, at least 55%
linkage to care among PWID and 80% linkage to care among the
general population would be required (see Supplemental
Materials found at https://doi.org/10.1016/j.vhri.2018.12.005). For
estimates lower than these, all eligible persons would be
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The 2018 campaign focuses on screening of high-risk  populations at MMT, 
NSP, and select family medicine clinics. This campaign will be absorbed by
PWID screening when launched and the ongoing efforts at family medicine
clinics would be captured under the “existing program.”
Opportunistic screening
The PWID population was defined to include both former and active injection
drug users since former users would have previously had high exposure to 








Both active and former needle and syringe exchange clients would be
targeted together, considering the social network dynamics of needle and 
syringe exchange users.
Established Ministry screening programs in Malaysia include initiatives
in dialysis centers and blood banks, as well as select family medicine clinics
Relapsed MMT Clients These MMT clients are no longer adhering to methadone maintenance
therapy. However, these individuals are known to MMT clinics.
Former PWID
2. PWID targeting
Baseline screening efforts represent ongoing HCV screening activities.
Year
Current MMT clients are actively adhering to methadone maintenance therapy. 
Annual HCV screening is currently required at MMT clinics but not enforced. 
Other active PWID
Opportunistic screening at tertiary hospitals will continue to occur
among patients that present with symptoms of advanced liver disease
These individuals are active PWID who are not currently linked to MMT or
NSP and have not previously received services. New platforms to reach
this group will be required.
Individuals to be screened in family medicine clinics represent the remaining 
undiagnosed population who have likely acquired HCV through medical or 
community transmission routes (blood transfusions, nosocomial infections, 
piercings, tattoos, etc) and are unaware of their risk for chronic HCV infection. 
New 2018 campaign
Existing Ministry screening 
program
These individuals are no longer active PWID but have a high HCV prevalence
due to previous exposure. New platforms to reach these PWID will be required.
3. General population screening:
High-risk screening in general
population
Fig. 1 – “Stepwise” screening approach schematic.
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required yield for each baseline activity or subgroup, confirma-
tory test coverage was determined after factoring in the preva-
lence of chronic infection status among persons anti-HCV
positive, which determines treatment eligibility and is informed
by confirmatory HCV core antigen testing. From required confir-
matory test coverage, anti-HCV test coverage was determined
after accounting for the prevalence of anti-HCV in the subpop-
ulation, which is informed by anti-HCV testing. HCV core antigenFig. 2 – Screening coverage calculation processtesting was selected because it is currently the cheapest confir-
matory test option in Malaysia. The prevalence of chronic
infection status was assumed to be identical across all groups.
Unique estimates of anti-HCV prevalence were used for sub-
groups. Key assumptions on anti-HCV prevalence, chronic
infection status, and linkage to care are presented for each sub-
group in Table 1.
Herein we provide further assumptions on how the coverage
estimates were calculated using the stepwise approach.diagram. HCV indicates hepatitis C virus.










Known patients 100% 100% 100% 12 5008
Existing Ministry of Health screening
efforts at dialysis centers, blood
blanks, and family medicine clincis
10%y 74%16 80% Unknown but assumed notification rate of
3000 annually remains constanty
Opportunistically screened by
specialists (inpatient)
100% 74%16 80% Assumed that 5% of treatment spots
would be filled by those
opportunistically screened annually
Anticipated 2018 campaign 63.1%17 74%16 55% 18 00017
PWID targeting
Current MMT clients 63.1%17 74%16 55% 18 00017
Current and former NSP clients 67.1%3 74%16 55% 85 17015,17,z
Relapsed MMT clients 67.1%3 74%16 55% 30 00015,17,x
Other active PWID 67.1%3 74%16 55% 36 83017,k
Former PWID 67.1%3 74%16 55% 229 2003,¶
General population screening
Adult population 2.5%3 74%16 80% 18.1 million3
High-risk groups in general population 2.9%£ 74%16 80% 6.4 million£
Delayed linkage to care population 100% 100% 100% This subgroup consists of all those who
are not successfully linked to care
across subgroups. This subgroup
continues to grow over time and 5% of
treatment targets are assumed to be
filled from delayed initiators.
HCV, hepatitis C virus; MMT, methadone maintenance therapy; NSP, needle and syringe exchange program; OST, opioid substitution therapy;
PWID, people who inject drugs.
* Chronic infection status represents the prevalence of chronic infection among anti-HCV positive individuals.
y Based on personal communication with R. Mohamed, MD (email communication, April 2018).
z On the basis of the Global AIDS Progress Report 2016,13 85% of PWID were reached through OST and NSP and 35% were reached through MMT
only. Therefore, approximately 50% of the 170000 active PWID were assumed to be reached only by NSP.
x On the basis of the Global AIDS Progress Report 2016,13 there are 10000 new MMT clients annually. About 30% of these clients, or 3000, relapse
annually.14 Over 10 years, this population size will grow to about 30 000 (assuming 3000 times 10).
k This figure was calculated as the number of remaining active PWID not in MMT and NSP programs, assuming there is a total of 170 000 active
PWID.13
¶ This figure was calculated as the remaining PWID population, assuming that the total current and former PWID population is 399 200.3
£ Calculated from the assumption of 144 312 non-PWID chronically HCV-infected persons, on the basis of 41% of total chronically HCV-infected
persons being non-PWID.3 The approximate population size of the high-risk groups within the general population was calculated after
assuming a 2.9% anti-HCV prevalence and chronically infected status of 74% among individuals anti-HCV positive.17 The highest prevalence
reported among risk sex/ethnicity strata in Malaysia was 2.9%.3 See Supplemental Materials for additional information.
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 Known patients: The backlog of known patients was assumed to
be treated in the first 3 years of the program. It was assumed
that no additional screening of already known patients would
be needed.
 Existing MMOH program: The existing MMOH screening program
at dialysis centers, blood banks, and a limited number of family
medicine clinics was assumed to yield 3000 chronic HCV cases
annually until 2023, on the basis of the estimated yield in 2017
(R. Mohamed, MD, email communication, April 2018). It was
assumed that after 2023, this yield would decline to 1000
chronic HCV cases annually by 2027 as the other active
screening initiatives were expanded.
 Opportunistic screening: Opportunistic screening among patients
with advanced liver disease in tertiary care centers was
assumed to yield 5% of the required treatment coverage annu-
ally in the early years, with this percentage decreasing to 2%
over time, because active screening efforts would kick in andmore patients would be diagnosed before the onset of serious
complications.
 2018 screening campaign: It was assumed that the screening
campaign launched in 2018 will yield 500 chronic HCV cases
annually (R. Mohamed, MD, email communication, April 2018).
From these yields, the required anti-HCV and confirmatory test
coverage was then calculated.PWID targeting
Once the annual national treatment targets became larger than
the yield from baseline activities, PWID targeting was initiated to
fill the gap. The remaining number of treatment spots to be filled
was determined after accounting for baseline activities, and then
the associated yield and anti-HCV and confirmatory test coverage
required were calculated as described previously. The NGO
campaign launched in 2018 working with private MMT and NSP
centers was assumed to be absorbed by scaled-up PWID targeting







Total cost per anti-HCV test
delivered
15.5/3.8 52.5/12.8
Anti-HCV test 2.5/0.6* 2.5/0.6*
Service delivery 13.0/3.218 50.0/12.219
Total cost per HCV core antigen
test delivered
62.0/15.1 99.0/24.1
HCV core antigen test 49.0/11.9* 49.0/11.9*
Service delivery 13.0/3.218 50.0/12.219
HCV indicates hepatitis C virus; MMT, methadone maintenance
therapy.
* Based on personal communication with R. Mohamed, MD (email
communication, April 2018).
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focused on one subgroup at a time (ie, current MMT clients, NSP
clients, relapsed MMT clients, other active PWID, and finally
former PWID). After full coverage of one subgroup was reached,
the next subgroup was targeted.
General population screening
After PWID targeting no longer yielded a sufficient number of
patients to meet the annual national targets to reach elimination
by 2030, general population screening filled any remaining annual
treatment gaps. The number of treatment spots to be filled was
determined after accounting for baseline screening and PWID
targeting. The required screening yield for these spots and asso-
ciated anti-HCV and confirmatory test coverage were calculated
as described previously.
To account for those individuals who were unsuccessfully
linked to care after being diagnosed, 5% of the ever-screened but
treatment-naive pool was assumed to initiate treatment each
year. Individuals from all subgroups contributed to this pool. No
data were available to inform this estimate, but we applied a
conservative approximation of 5% to avoid underestimating the
required additional screening each year from other subgroups.
Because the individuals in this pool had already been screened,
additional screening costs were not incurred.
It was assumed that sensitivity and specificity of anti-HCV
testing would be close to 100%, as indicated in the WHO guide-
lines.10 It was also assumed that all individuals who were offered
screening would give consent.
Calculating Screening Costs
Direct screening costs consisted of variable costs for screened
individuals and fixed program costs for capacity building. Total
variable costs were estimated by determining a cost per anti-HCV
test and HCV confirmatory test administered, and multiplying by
the relevant coverage estimates for each test. The cost per anti-
HCV test included the unit cost of the anti-HCV test kit and ser-
vice delivery. The cost per confirmatory diagnosis included the
unit cost for an HCV core antigen test and service delivery. Service
delivery costs were collected for PWID and other non-PWID sub-
groups separately (baseline screening, general population, etc),
because delivery platforms differ significantly. Unit costs are
presented in Table 2. Costs of liver disease staging were excluded.
Program costs for capacity building and demand generation
were also included, specifically for healthcare training and na-
tional awareness campaigns at MYR 3.2 million per year (~ $1
million). No national strategy exists for Malaysia, but benchmarks
based on strategic plans from other countries were used.2
Future costs were inflation-adjusted according to a rate of
2.5%. Costs are presented in bothMalaysian ringgit and US dollars.
The exchange rate on April 3, 2018 (1 MYR ¼ $0.26) was used.
Sensitivity Analysis
Estimates of linkage to care, the proportion of chronically infected
persons who begin treatment following diagnosis, in Malaysia are
highly uncertain. Some estimates exist for when interferon was
the standard of care (A. Azzeri et al, unpublished data, 2018), but
no data on linkage to care are available for the DAA era. Because of
lack of data on this proportion, a sensitivity analysis was con-
ducted on the linkage to care proportion for both PWID and the
general population. Specifically, we calculated the total coverage
requirements and total costs for a 5% increase in the baseline
linkage to care proportions to demonstrate the sensitivity of the
total coverage and cost estimates to this parameter. Sensitivity to
less effective linkage to care estimates was not explored because
the baseline linkage to care proportions represent the minimumvalues required to meet the 2030 targets. See Supplemental
Materials for further details.
Data Sources
Authors received permission to use data from sources involving
personal communications. All calculations were carried out in
Microsoft Excel. See Supplemental Materials for more information
on data sources.Results
Screening Coverage
In total, 6 million people would need to be screened between 2018
and 2030 under the stepwise strategy to meet the WHO treatment
targets. Relying on baseline screening efforts and PWID targeting
would result in a lower required screening coverage in the early
years. In 2018, year one at the time of the analysis, the total anti-
HCV test coverage required to treat 5 000 individuals would be
approximately 42 000. In 2024, the total number of individuals to
be screened would be approximately 105 500 to yield 25000 in-
dividuals initiated on treatment. General population screening
would have to be rolled out in 2026 to supplement PWID screening
activities, and by 2027 the required number of patients to be
screened annually would increase tomore than 1.4million to yield
30000 individuals initiated on treatment.
We describe herein the anti-HCV screening coverage required
within each phase of the program. Annual coverage requirements
for each subgroup for both anti-HCV and confirmatory testing can
be found in the Supplemental Materials.
Baseline screening activities
The pool of 12 500 known patients would be treated in the first 3
years, but these patients would not add to the required screening
coverage in those years. Existing MMOH screening programs
would continue screening about 40 600 patients each year, and the
2018 campaign would screen 1073 patients annually until 2020,
when targeted PWID screening would begin.
People who inject drugs
Starting in 2020, baseline screening would no longer yield enough
treatment-eligible persons to stay on pace with treatment targets.
PWID screening coverage would have to increase from about 5069




2018 2019 2020 2021 2022 2023 2024 2025 2026
Anti-HCV screening coverage targets 2018-2026, before general population screening
Known patients Existing Ministry screening program Opportunistic screening
2018 campaign Current MMT clients Current and former NSP clients
Relapsed MMT clients Other active PWID Former PWID
Fig. 3 – Anti-HCV screening coverage targets 2018-2026, before general population screening. HCV indicates hepatitis C
virus; MMT, methadone maintenance therapy; NSP, needle and syringe exchange program; PWID, people who inject drugs.
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subgroup to be screened from 2018 to 2026.
General population screening
The stepwise strategy would effectively delay the onset of general
population screening until 2026. Because of the lower anti-HCV
prevalence in the general population, total anti-HCV test
coveragewould spike tomore than 1.4million individuals per year
in 2027 to 2028 before dropping slightly to 1.2 million individuals











Current and former N
Current MMT clients
2018 campaign
Fig. 4 – Anti-HCV screening coverage targets 2018-2030. HCV in
therapy; NSP, needle and syringe exchange program; PWID, pebe screened would fall in the period 2026 to 2030. Figure 4 shows
required screening coverage for all subgroups, including among
the general population, for 2018 to 2030.
Estimated costs
The total cost of the national screening program was estimated at
MYR 222 million ($58 million). Annual costs were projected to
increase fromMYR 3.9million ($1.0million) in 2018 under baseline
screening efforts to MYR 9.5 million ($2.5 million) in 2025 under
PWID targeting. The costs were projected to reach MYR 31.62024 2025 2026 2027 2028 2029 2030
 targets 2018-2030
SP clients Opportunistic screening
Existing Ministry screening program
Known patients
dicates hepatitis C virus; MMT, methadone maintenance
ople who inject drugs.
Fig. 5 – Annual screening costs 2018-2030.
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screening effort (Fig. 5).Sensitivity Analysis
The total cost of the screening program was sensitive to the
linkage to care parameters. If the linkage to care proportion for the
PWID or the general population dropped even 5% below baseline
values, then the WHO treatment target could not be achieved by
2030, because an insufficient number of patients would be initi-
ated on treatment annually to sustain treatment targets.
If linkage to care proportions increased by 5%, then the
screening program would become less costly. For instance, if the
proportion linked to care after general population screening
improved from 80% to 85%, the total required number of total anti-
HCV screening coverage would be reduced to 5.6 million individ-
ualsdwhich is 0.4 million fewer than baselinedand the total cost
of the programwould drop toMYR 214million ($56million), which
is about 4% less than baseline. Nevertheless, if linkage to care
among PWID improved from 55% to 60%, total anti-HCV screening
coverage requirements and total program cost would be similar to
baseline, at 6 million individuals and MYR 220 million ($57
million). General population linkage to care had a greater influ-
ence on total coverage and costs because general population
screening accounts for more than 90% of the required screening
coverage.Discussion
This study is one of the first attempts to conduct an in-depth
analysis of the required screening coverage and estimated costs
of a national HCV elimination strategy. Although other studies
have discussed the costs and benefits of universal screening for
HCV, particularly in the United States and early adopting
LMICs,11e14 we have put forward a targeted stepwise approach
that demonstrates how targeted screening can give countries
more time to scale up a decentralized general population
screening program.
This stepwise approach indicated that a general population
screening program would not be required immediately to stay on
pace for elimination by 2030, and that targeting of high-risk sub-
groups could sustain progress toward meeting elimination treat-
ment targets for more than 5 years. This delay would provide avital window of time for the operational capacity of a decentral-
ized program to be developed. Malaysia's existing baseline
screening efforts are expected to be strong enough to sustain
progress toward treatment targets until 2020. In 2020, additional
screening scale-up would be needed, and we demonstrated that
by targeting PWID in the early years, more extensive general
population screening efforts could be delayed. After 2025, there
would be too few infected PWID to meet treatment targets, and
screening of the general population would ultimately have to kick
in to meet the WHO 2030 treatment targets.
In total, 6 million individuals would need to be screenedd
about one-fifth of Malaysia's current total population. At the peak
of the program, in the later years (2027-2030), about 1.2 to 1.4
million individuals would have to be screened each year.
Although large, this number appears feasible given that the
established Malaysian HIV/AIDS program screened 1.4 million
individuals in 2014,15 and that MMOH would have about 8 years
from the time of writing this paper to prepare the HCV program to
reach these HIV screening levels. Currently, HIV screening is
compulsory at premarital registration and is routinely done for
antenatal checkups.
The targeted stepwise approach would not only address
operational and capacity constraints by delaying general popula-
tion screening in the early years but also help minimize overall
screening costs during this period. Targeted PWID screening is
more efficient than general population screening because of the
greater yield per given number of individuals screened. In
Malaysia, the prevalence of HCV is estimated to be more than 20
times higher in PWID than in general population adults,3 which
implies that fewer PWID have to be screened to find one individual
eligible for treatment compared with members of the general
population.
If the stepwise approach is not adopted, and instead general
population screening is initiated from the start, approximately 7
million additional patients would need to be screened through
2030 with a total program cost estimated at MYR 317 million ($82
million). Thus, the stepwise screening strategy would be 40% less
costly, or save MYR 95 million ($24 million) compared with a
strategy that immediately adopts widespread general population
screening.
The current findings highlight the reality that an elimination
screening program will require substantial investment, and that
strategic planning for screening cannot be placed on the back
burner. At current expected DAA prices, screening costs represent
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costs, which have been estimated at MYR 3.6 billion ($890 million)
for a treatment scale-up scenario adequate to meet theWHO 2030
targets.7 As drug prices continue to drop on the basis of global
trends,1 screening will represent a growing proportion of the
overall HCV program cost. Efficiencies in screening test
manufacturing, procurement, and service delivery should be
identified to potentially lower the costs of the program.
An important secondary finding from this analysis is that if
linkage to care is poor, it will be impossible to meet the annual
treatment targets for elimination. The obtained linkage to care
proportion thresholds were 55% for PWID and 80% for the general
population. This finding highlights the need for supportive pol-
icies and initiatives that lead to improved case-finding, referral to
care, and initiation of therapy, as well as good rates of adherence
to treatment. There is limited existing evidence regarding effec-
tive interventions to improve linkage to care, but demonstration
studies are ongoing and these findings must be used to evaluate
the possible utility of solutions such as linkage workers or
incentive programs to promote both high rates of initial linkage to
care and long-term follow-up. The model results assumed that
delayed linkage to care is possible, suggesting that antiviral
therapy can be initiated at a later date for those patients who do
not wish or are not able to begin treatment immediately.
Our analysis points to additional HCV policy research prior-
ities. For instance, it may be beneficial to integrate screening
projections into a more advanced dynamic HCV transmission
model to incorporate projected changes in prevalence over time.
Our tool may have underestimated the coverage and costs
required in the later years of the program, when chronic HCV
prevalence among all subgroups is expected to decrease. We
implicitly assumed that potential decreases in prevalence would
be offset by otherdunaccounted fordfactors that have an effect
in the opposite direction, including potential price reductions in
anti-HCV tests and improved linkage to care as the program ma-
tures. We did not model possible growth of infected PWID sub-
populations and reinfection, but we also did not account for
mortality in the PWID population and this would partially balance
out any observed growth. Moreover, we did not account for in-
dividuals who wish to decline screening, but we recognize that all
individuals have the autonomy and right to informed consent and
could decline HCV screening when offered by a clinician. Looking
forward, HCV screening tools could also be improved to capture
more of the complexity of HCV screening and treatment dy-
namics, including population growth, reinfection of PWID, the
benefits of treatment as prevention, and consent.
The robustness of our coverage and cost estimates is also
limited by the quality of evidence that exists for current linkage to
care and the effectiveness of the cascade of care. A number of the
assumptions underlying our results are based on unpublished
sources, such as communications with clinicians and government
reports. In the absence of further validated estimates, the esti-
mates used in this article represent the best data for initiating
discussion around this important HCV policy topic. Additional
data collection, including updated seroprevalence studies, size
estimation of key populations, and evaluation of the level of
linkage to care achieved in the various subgroups should be
conducted.
This work represents an initial exercise to guide screening
strategy development in Malaysia. The main findings could be
used to plan and prepare for targeted screening of PWID starting
in the next few years and a general population-level program at
the primary care level in full effect about five years later, but there
are still details to be worked through if this strategy were to be
operationalized. Active PWID are very accessible in one sense,
because many already have contact with civil society organiza-
tions and health facilities through NSP and MMT programs.Nevertheless, how HCV screening will be integrated into current
services in a consistent way remains to be determined, and how
former drug users and other active users who do not interact with
these programs will be reached requires further discussion with
community stakeholders. A general population screening pro-
gram that covers more than a million people annually cannot be
launched overnight. Extensive discussion among Ministry of
Health officials, hepatologists, NGOs, and other stakeholders will
be required to address how resources from targeted screening
could be transferred to a general population screening program
and what other steps could be taken to prepare for this buildup
and successful decentralization. Finally, the means by which the
proposed screening strategy can fit within a longer term screening
strategy beyond 2030 will also have to be addressed.
We suggest that similar exercises estimating the coverage and
cost of HCV screening should be conducted in other countries that
are considering launching national HCV elimination programs. In
these settings, this exercise will assist in improving the under-
standing of the resources required and the implications of the
proposed screening strategy in terms of resource mobilization,
healthcare training, and other enabling activities. It is likely that a
stepwise strategy is practical only in a setting with an epidemio-
logical context with a significant burden among PWID, but each
country context will have to be fully evaluated.Conclusions
Finding the missing millions is a daunting challenge in HCV
elimination. Investment in a national screening program is
crucial; without effective identification of chronically infected
individuals, it will be impossible to meet treatment targets.
Because both financial and operational challenges can easily
impede screening efforts, it will be important to ensure that effi-
cient, cost-minimizing screening strategies are thoughtfully
designed and executed. These findingswill be useful for informing
the planning and launching of a large-scale national HCV
screening strategy in Malaysia. We hope this analysis will also
serve as a prototype that can aid other countries in the design and
implementation of national HCV screening programs.
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